

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

: Chul-Hee LEE et al.

Confirmation No. 2398

Group Art Unit: 1614

Appl. No.

: 10/533,077

Examiner: Not Yet Assigned

Filed

: April 28, 2005

For

: COMPOSITION FOR PREVENTING SECRETION OF IMMUNOGLOBULIN E-DEPENDENT HISTAMINE RELEASING FACTOR

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents U.S. Patent and Trademark Office Customer Window, Mail Stop Amendment Randolph Building 401 Dulany Street Alexandria, VA 22314

Sir:

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and §§1.97-1.98, Applicants hereby bring the following information to the attention of the Examiner in charge of the above-identified application, which includes information cited and discussed in the International Search Report issued in connection with International Patent Application No. PCT/KR2003/002332, of which the present application is a U.S. National Stage. A copy of the International Search Report (in English) was enclosed with the papers when entering the National Stage on April 28, 2005. The Examiner is invited to review these materials to inspect the relevance indicated in the International Search Report with respect to the documents cited therein. The following is a list of the documents cited in the above-noted International Search Report:

P27808.A02

- HAMAGUCHI Takuya et al., Int. Arch. Allergy Immunol., 2001, Vol. 126,
 No. 4, pp. 318-324.
- (2) OHMORI Yoshiyuki et al., Biol. Pharm. Bull., Vol. 18, No. 5, pp. 683-686, 1995.
- (3) U.S. Patent No. 6,369,091 B1 (Sircar et al.), April 9, 2002.
- (4) MACDONALD Susan M. et al., Proceeding of the National Academy of Sciences of the United States of America, 2001, Vol. 98, No. 19, pp. 10829-10832.
- (5) PASMANS SG et al., Am. J. Respir. Crit. Care Med., 1996, Vol. 154 (2 pt 1), pp. 318-323, abstract.
- (6) COREY JP, Otolaryngol. Head Neck Surg., 1993, Vol. 109 (3 Pt 2), pp. 584-592, abstract.
- (7) NISHIMURA N. et al., Immunopharmacol Immunotoxicol.,1997, Vol. 9, No. 5, pp. 511-521, abstract.
- (8) CHAND N. et al., Agents Actions, 1985, Vol. 16, No. 5, pp. 318-322, abstract.
- (9) U.S. Patent No. 6,271,390 B1 (Sircar et al.), August 7, 2001; Applicants note that this document is a family member of document (3).
- (10) U.S. Patent No. 6,303,645 B1 (Sircar et al.), October 16, 2001; Applicants note that this document is a family member of document (3).
- (11) U.S. Patent No. 6,451,829 B2 (Sircar et al.), September 17, 2002; Applicants note that this document is a family member of document (3).

- (12) U.S. Patent Application Publication No. US 2002/0010343 A1 (Sircar et al.), January 24, 2002; Applicants note that this document is a family member of document (3).
- (13) U.S. Patent Application Publication No. US 2002/0132808 A1 (Sircar et al), September 19, 2002; Applicants note that this document is a family member of document (3).
- (14) U.S. Patent Application Publication No. US 2003/0100582 A1 (Sircar et al.), May 29, 2003; Applicants note that this document is a family member of document (3).
- (15) U.S. Patent Application Publication No. US 2003/0004203 A1 (Sircar et al.), January 2, 2003; Applicants note that this document is a family member of document (3).
- (16) U.S. Patent Application Publication No. US 2004/0214821 A1 (Sircar et al.), October 28, 2004; Applicants note that this document is a family member of document (3).
- (17) U.S. Patent Application Publication No. US 2005/0075343 A1 (Sircar et al.), April 7, 2005; Applicants note that this document is a family member of document (3).

Copies of the above-noted documents except for the U.S. patents and U.S. Patent Applications cited above are enclosed together with a duly completed Form PTO-1449. The Examiner is accordingly requested to consider each of these documents, and to make them of record in this application by

P27808.A02

initialing in the appropriate spaces on the Form PTO-1449. Applicants

respectfully request that the Examiner include a copy of the initialed Form PTO-

1449 with the next communication from the U.S. Patent and Trademark Office.

Further to the U.S. Patent and Trademark Office's decision to partially

waive the requirements under 37 C.F.R. §1.98 (a)(2) (i) and (iii), copies of the

U.S. patents and U.S. patent applications cited above are not enclosed herewith.

However, if any copies are needed, the Examiner is respectfully requested to

contact the undersigned.

Applicants note that an Office Action on the merits has not issued in the

present application, and thus no fee is believed necessary to ensure

consideration of the submitted materials. However, if an Office Action on the

merits has issued and is crossing this statement in the mail, the undersigned

hereby authorizes the Patent and Trademark Office to charge any fee necessary

for the consideration of this statement, including any payment under 37 C.F.R.

§1.17 (p) to Deposit Account No. 19-0089.

Should there be any questions, the Examiner is invited to contact the

undersigned at the below-listed telephone number.

Respectfully Submitted,

Chul-Hee LEE et al.

Heribert F. Muensterer

7 Rea. No. 50.417

Bruce H. Bernstein

Reg. No. 29,027

August 11, 2005

GREENBLUM & BERNSTEIN, P.L.C.

1950 Roland Clarke Place

Reston, VA 20191

(703) 716-1191

4

P2	780	18	P05	.doc
1 4	, ,,	, O.	· uu	.uvc

~ 1	
Sheet	I of

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office							Atty. Docket No. Application No. 10/533,077									
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary ANS 1 2 2005 Filing Date Group																
· (Use several sheets if necessa						SHEET.	ART	April 28,	Filing Date April 28, 2005			Group 1614				
U.S. PARENTS																
EXAMINER INITIAL		DOCUMENT NUMBER									NAME	CLASS		BCLASS	FILING DATE IF APPROPRIATE	
		6 3 6 9 0 9 1			04/09/02											
		6	2	7	1	3	9	0	08/07/01	SIRCAF						
		6	3	0	3	6	4	5	10/16/01	SIRCAF						
		6	4	5	1	8	2	9	09/17/02	SIRCAF						
	2002	0	0	1	0	3	4	3	01/24/02	SIRCAF			_			
	2002	1/	1	3	2	8	0	8	09/19/02	SIRCAF			-			
	2003	0	1	0	0	5	8	2	05/29/03	SIRCAF						
	2003	0	0	0	4	2	0	3	01/02/03	SIRCAF		<u> </u>	-			
	2004	0	0	<u> 1</u> 7	<u>4</u> 5	<u>8</u> 3	2	<u>1</u> 3	04/07/05	SIRCAF			-			
	2003	1 0					-	_					<u> </u>		l	
FOREIGN PATENT DOCUMENTS TRANSLATION																
		DOCUMENT NUMBER							DATE	DATE COUNTRY C			SUB	CLASS	YES NO	
		<u> </u>														
						_										
		<u></u>					CLUM	CNT	C (Implications A.	the Title	Data Dartin	ant Banca St				
	1	الا	^ N A ^						S (Including Audi., Int. Arch.					4 pp 31	19 224	
	2	+		-											10-324.	
	3	OHMORI Yoshiyuki et al., Biol. Pharm. Bull., Vol. 18, No. 5, pp. 683-686, 1995. MACDONALD Susan M. et al., Proceeding of the National Academy of Sciences of the United States of America, 2001, Vol. 98, No. 19, pp. 10829-10832.														
	4	+											2 pt 1)	nn 318	-323 abs	tract
	5	+	PASMANS SG et al., Am. J. Respir. Crit. Care Med., 1996, Vol. 154 (2 pt 1), pp. 318-323, abstract. COREY JP, Otolaryngol. Head Neck Surg., 1993, Vol. 109 (3 Pt 2), pp. 584-592, abstract.													
	6	NISHIMURA N. et al., Immunopharmacol Immunotoxicol.,1997, Vol. 9, No. 5, pp. 511-521, abstract.														
	7	CHAND N. et al., Agents Actions, 1985, Vol. 16, No. 5, pp. 318-322, abstract.														
									<u> </u>			· · · · · · · · · · · · · · · · · · ·				
											· , · · ·					
												·				
EXAMINER										DA	TE CONS	IDERED				
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.																